World Health Organization Sounds Alert Over Critical Lack of Weight-Loss Injections
Less than 10% of individuals who could benefit from weight-loss injections such as Wegovy can access them, states the global health agency as it issues its first advice on the drugs.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for broader and more equitable access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The new guidance recognises that excess weight is a long-term condition that can be managed with comprehensive and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant obstacles to universal access to the injections that can help people shift substantial weight, notes the agency.
Skinny Jab Supply Crisis
Even under the present best projected outlook, the supply of such drugs would only suffice for around 100 million people – fewer than 10% of eligible patients, according to the WHO.
The guideline encourages countries and companies to widen availability, through measures such as voluntary licensing.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
How Weight-Loss Drugs Work
The injections replicate a biological compound to slow digestion, curb appetite and increase the sense of being full so users eat less.
Patients usually see weight reduction within a few weeks of commencing the regular doses.
Research suggests users may regain a significant portion within a year of discontinuing the medication, when their normal hunger return.
To be overweight or obese raises your likelihood for contracting health problems, like type 2 diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns individuals in all nations and was associated with millions of deaths worldwide in 2024, per the health agency.
